Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype
Author(s) -
Clancy J P,
Johnson S G,
Yee S W,
McDonagh E M,
Caudle K E,
Klein T E,
Cannavo M,
Giacomini K M
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.54
Subject(s) - ivacaftor , cystic fibrosis transmembrane conductance regulator , cystic fibrosis , context (archaeology) , pharmacogenetics , medicine , genotype , pharmacology , gene , genetics , biology , paleontology
Cystic fibrosis (CF) is a life‐shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D‐CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results. Clinical Pharmacology & Therapeutics (2014); 95 6, 592–597. doi: 10.1038/clpt.2014.54